Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05189184
Other study ID # HNSCC-R/M-01
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date March 30, 2022
Est. completion date March 30, 2025

Study information

Verified date December 2021
Source The First Affiliated Hospital of Zhengzhou University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, open-labelled study to evaluate the efficacy and safety of Camrelizumab in Combination With Apatinib mesylate Plus Albumin-bound paclitaxel and cisplatin as the First Line Treatment of Metastatic or Recurrent, UnresectableHead and Neck Squamous Cell Carcinoma. The objective response rate (ORR) will be evaluated as the primary endpoints.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date March 30, 2025
Est. primary completion date March 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1?Has fully understood and voluntarily signed an written Informed Consent and agreed to follow the research plan treatment and visiting plan; 2?Aged >=18 years; 3?Histologically confirmed recurrent or metastatic HNSCC of the oral cavity, oropharynx, hypopharynx, and/or larynx that is considered incurable by local therapies; 4?Eastern Cooperative Oncology Group (ECOG) performance status 0-1; 5?Expected survival period = 3 months; 6?Tumor tissue with PD-L1 detection (paraffin specimens or fresh tumor tissue within 2 years) can be provided or PD-L1 test report of tumor tissue samples issued by a state-approved qualification unit; 7?At least one measurable lesion, according to RECIST 1.1; 8?Toxicity of the subject has been restored to the =1 level defined by NCI-CTCAE V5.0 (except hair loss); 9?Patients must be able to swallow oral drugs and do not have significant affected gastrointestinal abnormalities, such as absorption adverse syndrome or most of the gastrointestinal tract; 10?The main function is normal, the test results at the time of screening must meet the following requirements: 1. Blood routine (no blood transfusion, erythropoietin (EPO), granulocyte-colony-stimulating factor (G-CSF) or granulocyte-macrophage-colony-stimulating factor (GM-CSF) within 14 days prior to screening) : A.Hemoglobin (HB) = 90 g / L; B.Absolute neutrophil count (ANC) of >= 1.5*10^9/L; C.platelet count of >= 100*10^9/L; 2. Biochemical examination needs to meet the following criteria: A.TBIL < 1.5 ULN (Gilbert syndrome patient, < 3 ULN); B.ALT and AST < 3 ULN, if there exists hepatic metastases, ALT and AST < 5 ULN; C.Cr <=1.5 ULN or CCr =50ml/min; 3. Echocardiography:LVEF=50%; 4. INR or PT <= 1.5 ULN, APTT <=1.5 ULN; 11?Contraception: Women of childbearing age should agree to use effective contraception during the study and for 6 months after the end of the study; Negative serum or urine pregnancy test within 7 days prior to study enrollment and must be non-lactating; Men who agreed to use contraception during the study period and for six months after the end of the study period. Exclusion Criteria: 1. Those who are allergic to drug treatment; 2. Disease that is suitable for local therapy administered with curative intent; 3. Accept system chemotherapy, but does not include a circulation of a multi-mode treatment for chemotherapy for local advanced diseases (this treatment end time must be 6 months from the first test for the first test); 4. Patients with local advanced head and neck squamous cell carcinoma have completed multi-mode chemotherapy completed within 6 months of disease progression; 5. It has received immunotherapy for anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti-CTLA-4 antibody or targeted to T cell common stimulation or immunoction point pathway; 6. There have been any malignant tumors in five years, except for other malignant tumors,cervical in situ cancer, non-melanoma skin cancer or other tumors / cancer that passively treats for at least 5 years without disease; 7. Anti-blood vessel treatment was received within 6 months before administration; 8. According to NCI CTCAEV5.0, there have been peripheral neuropathy = 2; 9. Accompanied by known active central nervous system transfer (CNS) and / or cancer meningitis: Previously received brain transfer subjects can participate in research, premise is the clinical stability for at least 2 weeks, no new or expanded brains Transfer evidence, and 14 days before the drug administration, steroids were stopped 14 days. The stable brain transfer in this definition should be determined before the study of drugs for the first time. The invisible brain transfer subject (ie there is no nervous system symptoms, no corticosteroids, no lesions> 1.5 cm) can participate, but need to periodically perform brain imaging in the disease site; 10. It has not been recovered from any acute impact of past surgery, chemotherapy or radiotherapy, ie, the subject of =1 (NCI CTCAEV5.0) (except for external hair loss), if the nutritional state is stable, it is allowed to radiotherapy and / or surgery Produced chronic advanced toxicity (pharyngeal / throat, namely oral dry, speech, swallowing abnormal); 11. Within 4 weeks or 4 weeks before the first administration, the anti-tumor drug treatment (such as chemotherapy, hormone therapy, immunotherapy, antibody treatment, radiotherapy, etc.), except for reducing pain on bones, except for bones; 12. It has received major surgery within the 4 weeks of the first administration or is expected to carry out major surgery during this study; 13. In the first 2 weeks or 2 weeks of the first administration, immunosuppressive drugs is required, and the following is eliminated: 1. intranasal, inhalation, external use steroids or local steroid injection (such as joint internal injection); 2. physiological doses of systemic corticosteroids (=10 mg / connone or equivalent dose); 3. A short-term (=7 days) use steroids to prevent or treat non-autoimmune allergic diseases; 14.?Subjects that are known to have active, or have a medical history and may relapse (such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, Patients with multiple hardening, vascular, glomerulitis, etc.), or high risk (such as receiving organ transplantation require immunotherapy). However, the following patients are allowed to be incorporated: patients with type I diabetic patients with fixed doses; only the autoimmune thyroid dysfunction of hormone replacement treatment; skin disease (such as eczema, occupancy) without systemic treatment 10% or less ramp, no opaque symptoms of psoriasis, etc.); 15?15. There is a significant clinical cardiovascular disease, including but not limited to acute myocardial infarction within 6 months of the group, severe / unstable angina or coronary and bridge; congestive heart failure New York Heart Association (NYHA) = 2 Level; arrhythmia (including QTC inter-male male = 450 ms, female = 470 ms); left ventricular ejection fraction (LVEF) <50%; 16?Under anti-hypertension treatment, still uncontrolled hypertension, defined as: systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg; 17?Urinalysis shows urine protein =2+ or 24-hour protein quantity test shows urinary protein =1 g; 18?History of mental drug abuse and unable to quit or have mental disabilities; 19?Active or uncontrolled severe infection; 20?It is known that there is a history of liver disease, including but not limited to known moonitis virus (HBV) infection and HBV DNA positive (=1 × 104 copy / ml); Hepatitis Hepatitis Virus infection (HCV) and HCV RNA positive (=1 × 103copy / ml), or cirrhosis, etc .; 21?Patients with pulmonary fibrosis, interstitial pneumonia, dust lung, radioactive pneumonia, drug-based pneumonia and severe lung function; 22?Pregnancy (pregnancy detection of pregnancy) or women underwater; 23?The first use of medication within 30 days or expected to vaccinate the vaccination during the study; 24?Subjects have or plans to receive physical organs or blood system transplants during the study (except corneal transplantation); 25?According to the judgment of the researcher, it is considered that it is not suitable for the group.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Camrelizumab+Apatinib mesylate+Albumin-bound paclitaxel+cisplatin
Camrelizumab in Combination With Apatinib mesylate Plus Albumin-bound paclitaxel and cisplatin as the First Line Treatment of Recurrent or Metastatic , UnresectableHead and Neck Squamous Cell Carcinoma (HNSCC)

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
The First Affiliated Hospital of Zhengzhou University Jiangsu HengRui Medicine Co., Ltd.

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Response Rate (CR+PR) Objective response rate (ORR) according to RECIST1.1 Time Frame: Up to 24 months
Secondary Overall survival (OS) Up to 24 months
Secondary Progression free survival (PFS) Progression free survival (PFS) according to RECIST 1.1 Up to 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT03317327 - REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors Phase 1/Phase 2
Terminated NCT02892201 - Pembrolizumab in HNSCC With Residual Disease After Radiation Phase 2
Active, not recruiting NCT04854499 - Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma Phase 2
Terminated NCT04110249 - Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and Neck Cancer N/A
Terminated NCT02495896 - Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Recruiting NCT05338905 - Intensive Symptom Surveillance Guided by Machine Learning-Directed Risk Stratification in Patients With Non-Metastatic Head and Neck Cancer, The INSIGHT Trial N/A
Recruiting NCT04045496 - A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors Phase 1
Completed NCT04452214 - A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors Phase 1
Recruiting NCT04096638 - Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT03070366 - Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC Phase 2
Recruiting NCT02661152 - DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC. Phase 3
Terminated NCT02488629 - Study of SCB01A in Patient With Head and Neck Cancer Phase 2
Completed NCT01697800 - A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract Phase 2
Completed NCT01427478 - Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck Phase 3
Recruiting NCT05437380 - Peritumoral Microbubbles and CEUS for SLN Detection and Biopsy in HNSCC N/A
Recruiting NCT05065086 - Single Modality Trans Oral Robotic Surgery for Primary Oropharyngeal Cancer: Exploring the Impact of Surgical Margins on Local Disease Recurrence
Completed NCT03022409 - A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC). Phase 1
Recruiting NCT04567056 - Specific Methylation Profiles in HNSCC